AbbVie to buy ImmunoGen for $10.1 billion to boost cancer drug portfolio
AbbVie said on Thursday it will buy drugmaker ImmunoGen for $10.1 billion, boosting its presence in the market
1970-01-01 08:00
Merck Discontinues Developing Drug Candidates With Sichuan Kelun After Daiichi Sankyo Deal
Merck & Co. won’t continue with two drug candidates it previously agreed to co-develop with a Chinese biotech
1970-01-01 08:00
Novartis Spinoff Sandoz to Start Trading as Standalone Drugmaker
Sandoz Group AG, the maker of copycat medicines, was spun off from drugmaker Novartis AG to begin life
1970-01-01 08:00
China Drug-Price Negotiations Offers Glimpse Into Future for Companies in US
As drugmakers in the US steel for price negotiations ushered in by President Joe Biden’s Inflation Reduction Act,
1970-01-01 08:00
AbbVie trims full-year profit forecast on higher R&D expenses
(Reuters) -AbbVie Inc cut its full-year profit forecast on Thursday, citing $280 million in milestone and in-process research and development
1970-01-01 08:00
Roivant Attracts Interest for $7 Billion-Plus Bowel Drug
Roivant Sciences Ltd. is attracting interest from large pharmaceutical companies for its treatment for inflammatory bowel disease, which
1970-01-01 08:00
Zuckerberg Is Helping to Propel Chicago’s Biotech Ambitions
For about a year, Northwestern University professor Shana Kelley and a group of more than 20 Chicago scientists
1970-01-01 08:00
Astra Drops Bowel Disease Drug Program After Delays
AstraZeneca Plc abandoned the development of a medicine in advanced tests called brazikumab for inflammatory bowel diseases like
1970-01-01 08:00
US FDA approves Genmab-AbbVie's blood cancer therapy
(Reuters) -The U.S. Food and Drug Administration has approved AbbVie Inc and Danish drugmaker Genmab's blood cancer therapy for adult
1970-01-01 08:00
Teva Plans to Cut Back Generic Drug Production Even As Shortages Intensify
Teva Pharmaceutical Industries Ltd. plans to cut back manufacturing of generic drugs, citing low profitability, at a time
1970-01-01 08:00
Drugmakers Eye $23 Billion Biotech Argenx Ahead of Key Data
European biotech firm Argenx SE is scheduled to release key drug trial data this summer. Deal-hungry Big Pharma
1970-01-01 08:00
Pfizer Sells $31 Billion of Bonds in Fourth-Largest Deal Ever
Pfizer Inc. sold $31 billion of debt in the fourth-largest US bond sale ever, according to a person
1970-01-01 08:00